Literature DB >> 15170445

The anti-angiogenic basis of metronomic chemotherapy.

Robert S Kerbel1, Barton A Kamen.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15170445     DOI： 10.1038/nrc1369

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  413 in total

1.  Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.

Authors:  Birgit Hotz; Marina V Backer; Joseph M Backer; Heinz-J Buhr; Hubert G Hotz
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

Review 2.  Metronomic chemotherapy: new rationale for new directions.

Authors:  Eddy Pasquier; Maria Kavallaris; Nicolas André
Journal:  Nat Rev Clin Oncol       Date:  2010-06-08       Impact factor: 66.675

3.  Vasohibin: the feedback on a new inhibitor of angiogenesis.

Authors:  Robert S Kerbel
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

Review 4.  Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.

Authors:  Shom Goel; Andus Hon-Kit Wong; Rakesh K Jain
Journal:  Cold Spring Harb Perspect Med       Date:  2012-03       Impact factor: 6.915

Review 5.  Weekly paclitaxel in the treatment of recurrent ovarian cancer.

Authors:  Richard D Baird; David S P Tan; Stan B Kaye
Journal:  Nat Rev Clin Oncol       Date:  2010-08-03       Impact factor: 66.675

6.  Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.

Authors:  William M Merritt; Alpa M Nick; Amy R Carroll; Chunhua Lu; Koji Matsuo; Melissa Dumble; Nicholas Jennings; Shuyun Zhang; Yvonne G Lin; Whitney A Spannuth; Aparna A Kamat; Rebecca L Stone; Mian M K Shahzad; Robert L Coleman; Rakesh Kumar; Anil K Sood
Journal:  Mol Cancer Ther       Date:  2010-04-06       Impact factor: 6.261

7.  Emerging strategies for the identification and targeting of cancer stem cells.

Authors:  Jun Dou; Ning Gu
Journal:  Tumour Biol       Date:  2010-03-25

8.  Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma.

Authors:  Jia Ruan; Peter Martin; Morton Coleman; Richard R Furman; Ken Cheung; Adam Faye; Rebecca Elstrom; Mark Lachs; Katherine A Hajjar; John P Leonard
Journal:  Cancer       Date:  2010-06-01       Impact factor: 6.860

9.  Nanochannel technology for constant delivery of chemotherapeutics: beyond metronomic administration.

Authors:  Alessandro Grattoni; Haifa Shen; Daniel Fine; Arturas Ziemys; Jaskaran S Gill; Lee Hudson; Sharath Hosali; Randy Goodall; Xuewu Liu; Mauro Ferrari
Journal:  Pharm Res       Date:  2010-07-01       Impact factor: 4.200

Review 10.  Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.

Authors:  Jie Ma; David J Waxman
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.